Brief: TransCode Therapeutics Completes Initial Dosing Of First Cohort In Phase 1 Clinical Trial With TTX-MC138
10/10/2024 12:03
Oct 10 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS COMPLETES INITIAL DOSING OF FIRST
COHORT
IN PHASE 1 CLINICAL TRIAL WITH TTX-MC138, A MICRORNA-TARGETED
TECHNOLOGY
* TRANSCODE THERAPEUTICS INC - NO SIGNIFICANT SAFETY OR DOSE
LIMITING TOXICITIES REPORTED
Source text for Eikon: ID:nGNX1CnWbV
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors